Nishino Michiya
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Cancer Cytopathol. 2016 Jan;124(1):14-27. doi: 10.1002/cncy.21612. Epub 2015 Sep 8.
Advances in the molecular characterization of thyroid cancers have fueled the development of genetic and gene expression-based tests for thyroid fine-needle aspirations. Collectively, these tests are designed to improve the diagnostic certainty of thyroid cytology. This review summarizes the early published experience with the commercially available versions of these tests: the Afirma Gene Expression Classifier, ThyGenX (formerly miRInform)/ThyraMIR, and ThyroSeq. Key differences in testing approaches and issues regarding test performance and interpretation are also discussed.
甲状腺癌分子特征研究的进展推动了基于基因和基因表达的甲状腺细针穿刺检测技术的发展。总体而言,这些检测旨在提高甲状腺细胞学诊断的准确性。本综述总结了这些检测商业化版本(Afirma基因表达分类器、ThyGenX(原miRInform)/ThyraMIR和ThyroSeq)早期发表的经验。还讨论了检测方法的主要差异以及有关检测性能和解读的问题。